Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...
Catalyst struck a deal Wednesday with Teva that will prevent the generic drugmaker from knocking off Firdapse until 2035.
Plus: Trinity Hunt Partners sells forensic expert witness firm Aperture, Rogers Healy’s VC fund invests to bring Foxtrot ...
Researchers have developed a new catalyst that uniquely increases in activity over time, unlike most that degrade. This ...
BofA keeps a Buy rating on Catalyst Pharmaceuticals (CPRX) with a $30 price target following the announcement of a Firdapse patent settlement ...
Zoom in: Catalyst was formed via an all-equity transaction between the department store chain JCPenney and Sparc Group's ...
It wasn’t just fact-checking that Meta scrapped from its platforms as it prepares for the second Trump administration.
Citi analyst Samantha Semenkow has maintained their bullish stance on CPRX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...
H1, a healthcare data analytics platform serving the pharmaceutical industry with data on over 10 million healthcare ...
The department store chain said that the all-equity merger brings its banner and various exclusive private brands under the ...